Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

233 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-08

Study Completion Date

2024-10-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter study aims to evaluate treatment adherence and satisfaction of patients with cutaneous lupus, influenced by perception of the disease, fear of side effects, cost of medications and the doctor-patient relationship. Adherence will be measured by a VAS of 80% or higher on the Medical Adherence Self-Report Inventory scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus

NCT02364908

Systemic Lupus Erythematosus

COMPLETED NA

Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus

NCT01904812

Lupus Erythematosus

COMPLETED NA

International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus

NCT01509989

Systemic Lupus Erythematosus

COMPLETED

Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus Patients

NCT05971498

Systemic Lupus Erythematosus

UNKNOWN

Lupus and Observance

NCT03019926

Systemic Lupus, Skin Lupus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicenter, cross-sectional study aims to characterize adherence to treatment and satisfaction of patients with cutaneous lupus. Non-adherence to treatment is a major problem, influenced by perception of the disease, fear of adverse effects, cost of medications and the doctor-patient relationship. Adherence will be measured by a VAS of 80% or more on the visual analog scale of the Medical Adherence Self-Report Inventory questionnaire.

The study is descriptive, multicenter and cross-sectional. Participants will be adult patients suffering from cutaneous lupus, diagnosed by a dermatologist and under treatment, able to complete questionnaires. Patients with systemic lupus, cognitive or psychiatric disorders will be excluded from the study.

The inclusion period is two years, with 30 minutes of follow-up per participant. The study will provide a better understanding of the feelings of patients with cutaneous lupus and the factors limiting their adherence to treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous Lupus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Questionnaires

Intervention Type OTHER

Responses to questionnaires:

* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
* Medical Adherence Self-Report Inventory (MASRI)
* Morisky Medication Adherence Scale (MMAS4)
* Visual analog scale (VAS) on the perception of disease control
* Belief on Medicine Questionnaire (BMQ)
* Care patient Feedback measure
* Hospital Anxiety and Depression Scale (HAD)
* Dermatology Life Quality Index (DLQI)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires

Responses to questionnaires:

* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
* Medical Adherence Self-Report Inventory (MASRI)
* Morisky Medication Adherence Scale (MMAS4)
* Visual analog scale (VAS) on the perception of disease control
* Belief on Medicine Questionnaire (BMQ)
* Care patient Feedback measure
* Hospital Anxiety and Depression Scale (HAD)
* Dermatology Life Quality Index (DLQI)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with cutaneous lupus (pure cutaneous or subacute) diagnosed by a dermatologist and under local and/or systemic treatment for cutaneous lupus
* No opposition to participation
* Patient able to complete the questionnaires
* Adult patient

Exclusion Criteria

* Systemic lupus with multiple visceral involvement
* Cognitive or psychiatric disorders preventing the smooth running of the study
* Pregnant woman
* Patient under guardianship/curatorship or safeguard of justice

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No